ANIP
ANI Pharmaceuticals, Inc.
ANIP's fundamentals are mixed, but it looks cheap: trading at 14x earnings, about a third of its usual 46x. Analysts expect strong earnings growth.
ANIP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
ANIP's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
ANIP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.5x | $71.06 | — |
| Current | 14x | $71.06 | — |
| Cheap | 21x | $103 | +45% |
| Fair | 46x | $228 | +221% |
| Expensive | 81x | $406 | +471% |
Historical ranges are pointers, not guarantees.
ANIP's PE is in its cheap range at 14x. If earnings grow as analysts expect, today's price would be 7.5x next year's earnings.
ANIP Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for ANIP, but weaker profitability.
ANIP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.52 | +91% |
| Q3 2026 | $4.98 | +188% |
| Q2 2026 | $4.60 | +$5.27 |
| Q1 2026 | $3.91 | +$5.08 |
| Q4 2025 | $3.32 | +$4.36 |
| Q3 2025 | $1.73 | +$2.27 |
| Q2 2025 | -$0.67 | -157% |
| Q1 2025 | -$1.17 | -173% |
| Q4 2024 | -$1.04 | -222% |
ANIP earned $4.98 per share over the past year, up 188% from the year before.
ANIP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $148.3M | +13% |
| Q2 2024 | $138M | +18% |
| Q1 2024 | $137.4M | +29% |
| Q4 2023 | $131.7M | +40% |
| Q3 2023 | $131.8M | +57% |
| Q2 2023 | $116.5M | +58% |
| Q1 2023 | $106.8M | +66% |
| Q4 2022 | $94.2M | +55% |
ANIP's revenue has grown year over year for 12 quarters in a row: $148M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -14% | -27 points |
| Q2 2024 | 3.7% | -6.9 points |
| Q1 2024 | 15% | +5.5 points |
| Q4 2023 | 5.1% | +3.2 points |
| Q3 2023 | 14% | +20 points |
| Q2 2023 | 11% | +28 points |
| Q1 2023 | 9.3% | +39 points |
| Q4 2022 | 1.9% | +41 points |
ANIP's operating margin was −14% last quarter, down 27 points from the same quarter a year ago.
ANIP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $70.3M | +85% |
| Q2 2026 | $53.6M | -25% |
| Q1 2026 | $52.3M | +61% |
| Q4 2025 | $29.1M | +116% |
| Q3 2025 | $38M | +395% |
| Q2 2025 | $71.8M | +454% |
| Q1 2025 | $32.5M | +138% |
| Q4 2024 | $13.5M | -68% |
ANIP generated $205M in free cash flow over the past year, up 32% from the year before.
ANIP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.1% | -240K shares |
| 1 year | +2.8% | +582K shares |
| 3 years | +13% | +2.5M shares |
| 5 years | +79% | +9.6M shares |
| Available history | +80% | +9.6M shares |
ANIP has 22M diluted shares, up 2.8% from a year ago, despite $35M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $13.6M |
| Q2 2026 | $813,000 |
| Q1 2026 | $19.8M |
| Q4 2025 | $611,000 |
| Q3 2025 | $1M |
| Q2 2025 | $551,000 |
| Q1 2025 | $10M |
| Q4 2024 | $318,000 |
ANIP spent $35M buying back its own shares over the past year, up 192% from the year before.
ANIP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ANIP has more cash than debt.
ANIP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 17.1 | Oversold |
ANIP's weekly RSI is 44 (neutral) and its Stochastic is 17 (oversold).
ANIP PE vs Healthcare Sector
| Metric | ANIP | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 1 | 29 | 28 pts below |
ANIP is trading at 14x earnings, a 45% discount to the Healthcare sector's median of 26x.
ANIP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.9 | 1.2% below |
| 20 week MA | $75.0 | 5.3% below |
| 50 week MA | $77.5 | 8.3% below |
| 100 week MA | $74.7 | 4.9% below |
| 200 week MA | $65.2 | 8.9% above |
ANIP has fallen below most of its moving averages, though it's still 8.9% above its 200-week average.
ANIP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.3 | $28.0 | -54% |
| 2021 | $28.0 | $50.9 | +82% |
| 2022 | $50.9 | $39.5 | -22% |
| 2023 | $39.5 | $55.1 | +40% |
| 2024 | $55.1 | $54.4 | -1.3% |
| 2025 | $54.4 | $82.4 | +51% |
| 2026 YTD | $82.4 | $71.1 | -14% |
ANIP has finished lower in three of the last six years. It's down 14% so far in 2026.